COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

癌症化疗的合作研究

• 批准号: 3556079
• 负责人: James A. Neidhart
• 金额: $ 18.95万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556079
• 关键词: acute leukemia; acute myelogenous leukemia; acute nonlymphocytic leukemia; adenocarcinoma; antineoplastics; biomarker; breast neoplasms; chlorambucil; chromosome translocation; cis platinum compound; clinical trials; colony stimulating factor; colorectal neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; cytosine arabinoside; daunorubicin; doxorubicin; flow cytometry; head /neck neoplasm; human subject; human therapy evaluation; interferon alpha; interferon gamma; interleukin 1; interleukin 2; interleukin 4; lymphocytic leukemia; lymphoma; melanoma; melphalan; metastasis; multidrug resistance; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; ovary neoplasms; pancreas neoplasms; polymerase chain reaction; prognosis; prostate neoplasms; renal cell carcinoma; squamous cell carcinoma; surface antigens; tumor necrosis factor alpha; uterus neoplasms

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immuno- therapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support. Specifi- cally, the University of New Mexico flow lab will function as one of the referral institutions performing flow cytometry for the Southwest Oncology Group. UNM will also continue to perform cell surface marker analyses on various Southwest Oncology Group leukemia protocols. The University of New Mexico has been a major scientific contributor to the Southwest Oncology Group in the past and this will remain one of the institution's top priorities. In addition, the recruitment of medically underserved populations (specifically Hispanic and American Indian) and women to Southwest Oncology Group studies will continue to be a major commitment of the University of New Mexico.

癌症患者将接受 III 期方案的治疗 西南肿瘤学小组采用跨学科方法利用 手术、放疗、化疗（包括可变的时间表 和药物组合，包括研究药物和 已经被证明和接受的药物，无论是单独使用还是与其他药物联合使用 放射治疗；这些形式的治疗将代表当前最 通过小组研究确定的有效药物组合）和免疫- 治疗。 对上述治疗无反应的患者将被 使用经过仔细评估的新实验剂进行管理 剂量和毒性，并显示出抗肿瘤的暗示证据 对特定的恶性肿瘤有作用。 这些将代表第二阶段 西南肿瘤学组的方案研究。 利用上述评估的患者材料进行辅助研究 协议将与其他研究活动协调 病理学、免疫学、生物化学等部门， 通过独立拨款支持进行药理学和解剖学研究。 具体- 特别是，新墨西哥大学流动实验室将作为其中之一 为西南地区进行流式细胞术的转诊机构 肿瘤学组。 新墨西哥州还将继续进行细胞表面标记 对各种西南肿瘤学组白血病方案的分析。 新墨西哥大学是重要的科学贡献者 西南肿瘤学组过去是，这仍将是西南肿瘤学组之一 机构的首要任务。 此外，还招聘医疗人员 服务不足的人群（特别是西班牙裔和美洲印第安人）以及 西南肿瘤学组的女性研究仍将是一个主要领域 新墨西哥大学的承诺。